No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Breaking Down Accolade: 8 Analysts Share Their Views
Accolade Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Accolade(ACCD.US) With Hold Rating, Cuts Target Price to $5
FDA Roundup: December 17, 2024
Accolade to Announce Fiscal Third Quarter 2025 Financial Results
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler